🔗 Visit the ClinicalTrials.gov page for NCT04597593
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. | Chest | 2010 | 10.29 |
| 2 | Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. | J Thromb Haemost | 2005 | 5.92 |
| 3 | National trends in oral anticoagulant use in the United States, 2007 to 2011. | Circ Cardiovasc Qual Outcomes | 2012 | 2.27 |
| 4 | Pros and cons of new oral anticoagulants. | Hematology Am Soc Hematol Educ Program | 2013 | 1.29 |
| 5 | Reversal of warfarin-induced hemorrhage in the emergency department. | West J Emerg Med | 2011 | 0.82 |
| 6 | Pharmacogenetics of dabigatran etexilate interindividual variability. | Thromb Res | 2016 | 0.77 |
| 7 | Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. | Biochem Pharmacol | 2016 | 0.75 |
| 8 | Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. | Front Pharmacol | 2016 | 0.75 |